M&A / Deals Parexel buys Vitrana to boost patient safety toolkit PharmaphorumContract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) Pharmaphorum Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum. Read full story Post navigation Previous: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNext: Merck still sees ‘compelling’ outlook for Terns leukemia drug Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026